Clinical Trials
Clinical Trials
Race Oncology is aiming to improve the lives of cancer patients by developing novel chemotherapy treatments that target cancer while protecting the heart.
RAC-010: A study of the safety and pharmacokinetics of RC220 in combination with doxorubicin in adult participants with solid tumours
Race Oncology is undertaking a Phase 1 clinical trial to investigate the safety, tolerability and pharmacokinetics of RC220 bisantrene in combination with doxorubicin in patients with advanced solid tumour cancers.
This trial will be conducted at several sites in Australia, Hong Kong and South Korea.
Trial Status: Active, not yet recruiting
For additional information about the trial including entry criteria for involvement and clinical site locations, please visit the website by clicking the button below:
Race Oncology is not able to provide medical advice or advise if this trial would be the best option for an individual cancer patient.
We encourage all patients and carers interested in this trial to speak to their treating doctor and/or to contact their closest clinical trial site for more information.
For enquiries, please contact Race Oncology at: trials@raceoncology.com.
